Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions

Ann Oncol. 2022 Nov;33(11):1091-1093. doi: 10.1016/j.annonc.2022.08.088. Epub 2022 Sep 9.

Authors

G Bianchini¹, L Licata², G Viale², L Gianni³

Affiliations

¹ Breast Cancer Group, Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy. Electronic address: bianchini.giampaolo@hsr.it.
² Breast Cancer Group, Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
³ Fondazione Michelangelo, Milan, Italy.

PMID: 36096335
DOI: 10.1016/j.annonc.2022.08.088

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Immunologic Factors / therapeutic use
Immunotherapy
Neoadjuvant Therapy
Triple Negative Breast Neoplasms* / drug therapy

Substances

Immunologic Factors